Stock Earnings
Analysts review Syndax Pharmaceuticals Inc’s rating
Syndax Pharmaceuticals Inc’s recently made public that its Chief Financial Officer Goldan Keith A. unloaded Company’s shares for reported $12033.0
Menu
Syndax Pharmaceuticals Inc’s recently made public that its Chief Financial Officer Goldan Keith A. unloaded Company’s shares for reported $12033.0
Syndax Pharmaceuticals Inc’s recently made public that its Chief Financial Officer Goldan Keith A. unloaded Company’s shares for reported $12033.0
In a filing, Syndax Pharmaceuticals Inc revealed its Head of R&D, CMO Botwood Nicholas A.J. acquired Company’s shares for reported
Syndax Pharmaceuticals, Inc. (SNDX), a clinical-stage healthcare company that focuses on an HDAC inhibitor for tumors and specializes in cancer